Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori

被引:6
作者
Bardhan, KD
Morton, D
Perry, MJ
Sanders, DS
Morris, P
Rowland, A
Thompson, M
Mitchell, TR
Roberts, PM
机构
[1] Rotherham Dist Gen Hosp NHS Trust, Rotherham S60 2UD, S Yorkshire, England
[2] Glaxo Wellcome R&D, Greenford, Middx, England
关键词
D O I
10.1046/j.1365-2036.2001.01040.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Both triple therapy with ranitidine bismuth citrate (RBC) plus two antibiotics for 7 days and dual therapy of RBC with clarithromycin for 14 days have been extensively studied; both regimens effectively eradicate Helicobacter pylori. However, few studies have assessed the efficacy of dual therapy given for 7 days. Aim: To compare the efficacy and safety of RBC 400 mg with clarithromycin 500 mg, alone or with metronidazole 400 mg, given twice daily for 7 days for the eradication of H. pylori. Methods: This single centre, randomized, double-blind study involved 118 patients with dyspepsia or a history of peptic ulcer disease. H. pylori infection was detected initially by CLO test, and confirmed in 109 patients by urea breath test and/or microbiology culture. H. pylori eradication was assessed 4 and 12 weeks after the end of treatment by urea breath test. H. pylori antibiotic susceptibility was assessed pre-study in all patients, and post-treatment in patients with a positive post-treatment urea breath test. Adverse events were recorded throughout the study. Results: H. pylori was eradicated in 93% of patients who received RBC with clarithromycin and metronidazole and in 84% of patients who received RBC with clarithromycin (intention-to-treat rates). Per protocol eradication rates were 98% and 90% for triple therapy and dual therapy, respectively. The eradication of metronidazole-resistant H. pylori was achieved in 100% and 88% of patients following dual therapy and triple therapy, respectively, and acquired resistance to clarithromycin occurred in only one patient following treatment failure. Both treatments were well-tolerated; only one patient (2%) was withdrawn from each treatment group due to adverse events. Conclusions: RBC with clarithromycin and metronidazole is a highly effective and well-tolerated triple therapy regimen for the eradication of H. pylori. RBC with clarithromycin dual therapy has a similar efficacy, and offers an alternative to triple therapy when there are concerns about treatment with metronidazole or the use of multiple antibiotics. Both regimens are effective against antibiotic-resistant strains of H. pylori.
引用
收藏
页码:1199 / 1204
页数:6
相关论文
共 18 条
[11]  
OSATO M, 1998, GASTROENTEROLOGY, V114, pA908
[13]   Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori [J].
Pipkin, GA ;
Williamson, R ;
Wood, JR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1998, 12 (09) :823-837
[14]   Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: A review [J].
Pipkin, GA ;
Dixon, JS ;
Williamson, R ;
Wood, JR .
HELICOBACTER, 1997, 2 (04) :159-171
[15]  
Pozzato P, 1998, ALIMENT PHARM THERAP, V12, P447
[16]  
Thjodleifsson B., 1998, Gastroenterology, V114, pA310, DOI 10.1016/S0016-5085(98)81257-2
[17]  
van der Wouden EJ, 1998, GASTROENTEROLOGY, V114, pA323
[18]   What are appropriate end-points for Helicobacter pylori eradication in the treatment of duodenal ulcer? [J].
Williams, MP ;
Pounder, RE .
DRUGS, 1998, 56 (01) :1-10